HCV infection and dialysis mortality

HCV infection and dialysis mortality is a clinical and epidemiological relationship in which hepatitis C virus infection marks an independently higher risk of death among patients with end-stage renal disease receiving dialysis. The evidence links infection not only to overall mortality but especially to liver-related death, while the comparison with transplantation complicates any simple conclusion: HCV-positive patients remain at elevated risk after transplantation, yet transplantation is still generally associated with better survival than continued dialysis when advanced liver injury does not preclude kidney transplantation alone.

Evidence of Excess Mortality

Longitudinal studies have repeatedly found an independent and significant association between anti-HCV antibody positivity and reduced survival among patients on long-term dialysis. A meta-analysis of seven observational studies including 11,589 dialysis patients estimated a relative risk of mortality of 1.34, with a 95% confidence interval of 1.33–1.86. The excess was particularly concentrated in liver-related outcomes: hepatocellular carcinoma and cirrhosis were significantly more frequent causes of death among anti-HCV antibody-positive patients, and the unadjusted relative risk of liver-related mortality was 5.89 compared with anti-HCV antibody-negative patients.

Large registry and population studies reinforce the same pattern. In a 10-year Australian and New Zealand cohort of 23,046 patients, anti-HCV-positive serologic status was independently associated with all-cause mortality, with a hazard ratio of 1.25 and a 95% confidence interval of 1.07–1.46. Hepatic failure was much more common as a cause of death in the anti-HCV-positive group, with an adjusted hazard ratio of 5.79, although its absolute rate remained low at 0.34 deaths per 100 patients per year. In a Japanese cohort of 76,201 dialysis patients, anti-HCV antibody independently predicted all-cause mortality with a relative risk of 1.37. A separate Australian and New Zealand cohort of 21,487 patients found increased mortality both in those anti-HCV-positive at baseline and in those who acquired anti-HCV antibody during dialysis.

The relationship is also visible in the Dialysis Outcomes and Practice Patterns Study, which covered patients receiving regular dialysis across three continents. Positive anti-HCV antibody was independently associated with mortality, with an adjusted relative risk of 1.17. Across these studies, the consistent direction of the association matters: the findings do not portray HCV as merely a laboratory marker accompanying severe renal disease, but as a persistent prognostic signal after adjustment for relevant clinical factors.

Waiting, Screening, and Competing Risks

Mortality risk is embedded in a longer institutional process of screening, surveillance, and transplant eligibility. All kidney transplant candidates should initially be screened for anti-HCV antibody and, where appropriate, active viremia by nucleic acid testing. Studies cited in the transplant evaluation literature found advanced liver injury, including stage 3 or 4 fibrosis and cirrhosis, in 10–25% of pre-kidney transplant candidates who underwent biopsy. Because established or decompensated cirrhosis may require referral for simultaneous liver-kidney transplantation rather than kidney transplantation alone, identifying liver disease changes the route through which a patient can pursue survival beyond dialysis.

The waiting list itself is a period of competing risks rather than a neutral pause. In some areas of the United States, deceased-donor kidney waiting times approach five to seven years. During that interval, patients with active HCV infection require regular assessment to determine whether liver disease has progressed enough to make kidney-alone transplantation unsuitable. Patients who have achieved a sustained virological response should undergo at least annual nucleic acid testing to confirm that the response persists. Patients who remain viremic should receive annual assessment of liver disease; those with Metavir stage 1 or 2 fibrosis were advised to undergo repeat biopsy every five years, while those with stage 3 fibrosis were to be reassessed after three years. Progression to early or established cirrhosis could lead to removal from the kidney waiting list and referral to a liver transplant team.

Death on the waiting list may occur before liver disease becomes the decisive event. In a single-center study of HCV-infected kidney candidates, diabetes was more prevalent among the HCV-infected cohort and was the only usual clinical variable associated with death in a Cox regression model, with a hazard ratio of 2.17. Liver disease itself was not predictive in that model. The result places HCV-related mortality within a broader field of cardiovascular and metabolic vulnerability: infection may increase risk, but diabetes, cardiovascular disease, waiting time, and the possibility of progressive liver injury determine how that risk is expressed.

Transplantation Versus Continued Dialysis

The survival comparison between transplantation and continued dialysis is central to the clinical meaning of HCV-associated mortality. Although HCV-positive kidney recipients have worse long-term survival than recipients without evidence of infection, transplantation still confers a survival advantage over remaining on dialysis for properly selected patients. Earlier analyses found significantly lower mortality among anti-HCV-positive patients who received a kidney transplant than among those who remained on dialysis. Pereira and colleagues reported a relative risk of death of 0.31 during the 7–48 months after transplantation compared with patients remaining on the waiting list.

A time-dependent analysis of 175 listed transplant candidates with documented HCV infection shows why the timing of risk must be handled carefully. The hazard ratio for death was 2.51 during the first six months after transplantation, but fell to 0.32 during the period from seven to 84 months after transplantation. Early postoperative vulnerability therefore coexisted with a pronounced later survival benefit. The evidence does not support treating the immediate post-transplant period and the subsequent years as a single undifferentiated interval.

The overall conclusion is correspondingly conditional rather than absolute. HCV infection increases mortality among kidney transplant recipients compared with noninfected recipients, and infection-related deaths after transplantation warrant further study of immunosuppressive regimens. Nevertheless, transplantation remains the preferred form of renal replacement therapy for an HCV-infected patient with end-stage renal disease when pretransplant liver biopsy does not show advanced liver injury. Patients unable to receive, tolerate, or respond to antiviral therapy should not automatically be confined to dialysis: despite active viremia, their long-term course may still be more favorable after transplantation.

Liver Disease, Graft Outcomes, and Organ Allocation

The mortality relationship cannot be separated from the condition of the liver before transplantation. Patients with established or decompensated cirrhosis face increased perioperative morbidity and mortality, greater susceptibility to infectious and metabolic complications, and inferior long-term survival. A consensus approach proposed using portal hypertension criteria to distinguish candidates for kidney transplantation alone from those who should be considered for simultaneous liver-kidney transplantation. In well-compensated cirrhosis, a wedge hepatic vein pressure below 10 mm Hg was proposed as a criterion for kidney transplantation alone, with the absence of varices on endoscopy and a platelet count above 120 × 10^3/µl also used in some programs. In one small series, 10-year survival after transplantation was only 26% among the few patients with pretransplant cirrhosis.

HCV also affects the fate of the transplanted kidney. In a comparison of 488 anti-HCV-positive recipients with 2,877 seronegative recipients, the adjusted relative risk of graft loss was 1.53. Registry data from Australia and New Zealand found worse five-year graft survival in the anti-HCV-positive cohort, with an adjusted hazard ratio for graft failure of 1.71. Graft loss was more often attributed to glomerulonephritis and chronic allograft nephropathy in the HCV-positive group. These graft complications matter to mortality because loss of graft function can return a patient to dialysis, where the underlying infection-associated risk remains active.

Organ allocation policies introduce another layer of risk and opportunity. Because organ supply is far below demand, kidneys from HCV-positive donors have sometimes been considered for HCV-positive recipients rather than discarded. In an American registry analysis, HCV-positive recipients who received such kidneys waited 310 fewer days than the average patient at their center and 395 fewer days than comparable recipients who waited for HCV-negative kidneys. Receiving an HCV-positive kidney was independently associated with better survival than remaining on the waiting list, with an adjusted hazard ratio of 0.76.

Long-term Spanish data comparing 162 HCV-positive recipients of kidneys from HCV-positive donors with 306 HCV-positive recipients of kidneys from HCV-negative donors found no difference in patient survival. Liver-related deaths were scarce in both groups, numbering three in the HCV-positive-donor group and two in the HCV-negative-donor group. Although graft survival without censoring for death was lower among recipients of HCV-positive kidneys, donor seropositivity was not an independent risk factor for death or graft loss after multivariate analysis. The evidence therefore supports a carefully restricted policy rather than universal acceptance or universal exclusion: HCV-positive kidneys should be offered to candidates with positive HCV RNA who have consented in advance, while avoiding unnecessary transmission to HCV-negative recipients.

Prevention and Clinical Significance

The mortality relationship begins before transplantation, in the dialysis unit. A review of 20 molecular virology studies involving newly diagnosed HCV-positive hemodialysis patients found that no study conclusively established the precise transmission route, but every study implicated failures in infection-control procedures as the probable cause. In 18 of the 20 studies, some or all new cases did not share a dialysis machine with the source patient. The internal dialysis-machine circuit therefore appeared to play, if any, only a small role in nosocomial transmission. On that evidence, dedicated machines for HCV-infected patients were not recommended, and isolation in a separate ward was likewise not recommended as a substitute for strict infection-control procedures.

The policy consequence is a shift from separating infected bodies to controlling unsafe procedures. Screening, confirmation of active viremia, surveillance while waiting, staging of liver disease, and treatment decisions collectively determine whether HCV-associated risk is detected early enough to alter its course. Pretransplant antiviral treatment may reduce post-transplant HCV-related glomerular disease and could lessen some complications, but treatment may be prolonged, expensive, poorly tolerated, and limited by nonresponse; interferon after transplantation is associated with increased allograft rejection, so eradication efforts should be concentrated before transplantation when possible.

HCV infection and dialysis mortality is therefore neither a single laboratory association nor an inevitable terminal sequence. It is a measurable excess risk produced through several interacting pathways: liver-related death, metabolic and cardiovascular vulnerability, time spent waiting for a kidney, infection-control failures, and the complications of transplantation and immunosuppression. The evidence gives the relationship a practical direction. Prevent transmission, identify active infection, monitor patients whose waiting time exposes them to progression, reserve kidney-alone transplantation for those without advanced liver injury, and weigh the substantial survival benefit of transplantation against the distinct early and late hazards that HCV creates.